Рубрика: ASO

Начало набора участников клинического испытания ATTUNE

The ATTUNE trial is a Phase 1/2 clinical study sponsored by Ionis. It aims to evaluate ION440, an investigational Antisense Oligonucleotide (ASO) therapy designed to address the root cause of MECP2 Duplication Syndrome (MDS).

ION440: IONIS выводит сообщество MDS на новый уровень

Written by David and verified by Ionis Following Ionis’ recent announcement about the upcoming clinical trial, we aim to provide a clearer understanding of this trial. It is especially important for families considering enrolling their child to know what a clinical trial is, particularly in the context of rare diseases like MECP2 Duplication Syndrome (MDS). […]